News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Seeking Alpha Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides the Q2 net income from continuing operations for Kyntra Bio Inc. The content seems to be a financial document detailing this specific metric.
Kyntra Bio (KYNB) reported a Q2 loss of $4.68 per share, missing the Zacks Consensus Estimate of a $3.18 loss, and revenues of -$1.47 million, significantly below the estimated figures. The company's shares have fallen 19.1% year-to-date, contrasting with the S&P 500's 13.2% gain. …
Kyntra Bio (Nasdaq: KYNB) reported its second-quarter 2026 financial results, highlighting a net income of $12.0 million due to a significant gain from subsidiary deconsolidation. The company finished the quarter with $95.7 million in cash, expected to fund operations into 2028. Key pipeline advancements …
Kyntra Bio announced its second quarter 2026 financial results and provided a business update, highlighting significant progress in its oncology and rare disease pipeline. The company is on track for interim analysis of its Phase 2 trial for FG-3246 in mCRPC and aims to …
* FibroGen (KYNB [https://seekingalpha.com/symbol/KYNB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, after market close. * The consensus EPS estimate is -$3.18, [https://seekingalpha.com/symbol/KYNB/earnings/estimates] and the consensus revenue estimate is $2.01M (+48.9% Y/Y). * Over the last 3 months, EPS estimates have …
Sharemaestro market context Price above Trend Line 52 weeks -35.8% · Next-week setup negative 24.9%Kyntra Bio, Inc. (KYNB) is scheduled to release its Q2'26 earnings on August 10. Analysts anticipate Q2'26 revenue to be 2.09 million USD, with an estimated Earnings Per Share (EPS) of (3.18) USD. The article provides a detailed table comparing reported and estimated revenues …
Kyntra Bio (Nasdaq: KYNB) will release its second quarter 2026 financial results on August 13, 2026, after market close, followed by a conference call and webcast at 5:00 PM Eastern Time. The company will discuss its financial performance and provide a business update, including …
Kyntra Bio, Inc. (Nasdaq: KYNB) announced it will release its second quarter 2026 financial results on Thursday, August 13, after market close. The company will also host a conference call and webcast at 5:00 PM Eastern Time on the same day to discuss its …
Kyntra Bio (KYNB) is anticipated to surpass earnings estimates for the quarter ended June 2026, with a projected year-over-year increase in earnings and revenues. The company's positive Earnings ESP of +5.44% combined with a Zacks Rank #3 suggests a strong likelihood of an EPS …
This article provides an overview of Kyntra Bio, Inc.'s (KYNB) Q3 2022 earnings report. The company missed both EPS and revenue expectations, reporting an actual EPS of -$24.50 against a consensus of -$20.25, and actual revenue of $15.73M compared to an expected $31.62M, marking …
Kyntra Bio, Inc. (NASDAQ: KYNB) generated $6.40 million in revenue last year, with its Novel Therapeutics segment contributing the most at $6.44 million. This represents a decrease from the previous year's $29.62 million from the same segment. Europe was the largest regional contributor, accounting …
Sharemaestro market context Price above Trend Line 52 weeks -35.8% · Next-week setup negative 24.9%Kyntra Bio, Inc. (KYNB) is a biopharmaceutical company focused on developing treatments for anemia, fibrotic disorders, and cancer. The article provides current stock data, including its market cap of $496.14M, a 52-week range of $109.00 to $273.00, and an upcoming earnings report on August …
Search by ticker symbol or company name and select a result to open its chart.